[1] Kang DY, Ahn JM, Yun SC, et al. Optical coherence tomography-guided or intravascular ultrasound-guided percutaneous coronary intervention: the OCTIVUS randomized clinical trial[J]. Circulation,2023,148(16):1195-1206. DOI: 10.1161/CIRCULATIONAHA.123.066429.
[2] Pan Q, Peng Y, Ni H, et al. Blood-urea-nitrogen-to-serum-albumin ratio in predicting the value of patients with contrast-induced nephropathy for coronary heart disease[J]. Int Urol Nephrol, 2024, 56(6): 2075-2083. DOI: 10.1007/s11255-023-03915-4.
[3] Ali ZA, Escaned J, Dudek D, et al. Strategies for renal protection in cardiovascular interventions[J]. Korean Circ J, 2022, 52(7): 485-495. DOI: 10.4070/kcj.2022.0093.
[4] Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation[J]. Kidney Med, 2020, 294(3): 660-668. DOI:10.1016/j.xkme.2020.01.001.
[5] Chen F, Lu J, Yang X, et al. Different hydration methods for the prevention of contrast-induced nephropathy in patients with elective percutaneous coronary intervention: a retrospective study[J]. BMC Cardiovasc Disord, 2023, 23(1):323. DOI: 10.1186/s12872-023-03358-w.
[6] Cui X, Xie B, Wang H, et al. Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore),2023,102(11):e33273. DOI: 10.1097/MD.0000000000033273.
[7] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019, 74(10):e177-e232. DOI: 10.1016/j.jacc.2019.03.010.
[8] Kusirisin P, Apaijai N, Noppakun K, et al. Circulating mitochondrial dysfunction as an early biomarker for contrast media-induced acute kidney injury in chronic kidney disease patients[J]. J Cell Mol Med, 2023, 27(14): 2059-2070. DOI: 10.1111/jcmm.17806.
[9] Sarhan II, Abdellatif YA, Saad RE, et al. Renoprotective effect of febuxostat on contrast-induced acute kidney injury in chronic kidney disease patients stage 3: randomized controlled trial[J]. BMC Nephrol, 2023, 24(1): 65. DOI: 10.1186/s12882-023-03114-4.
[10] Lin J, Chen J, Wu D, et al. Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: a systematic review and meta-analysis[J]. Angiology,2022,73(3):207-217.
[11] Khan F R, Nawaz T, Sajjad W, et al. Evaluating the differential risk of contrast-induced nephropathy among diabetic and non-diabetic patients following percutaneous coronary intervention[J]. Cureus,2024,16(2):e53493. DOI: 10.7759/cureus.53493.
[12] Faggioni M, Mehran R. Preventing contrast-induced renal failure: a guide[J]. Interv Cardiol, 2016, 11(2): 98-104. DOI: 10.15420/icr.2016:10:2.
[13] Bugani G, Ponticelli F, Giannini F, et al. Practical guide to prevention of contrast-induced acute kidney injury after percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2021, 97(3): 443-450. DOI: 10.1002/ccd.28740.
[14] 裘齐宁,李晓烨,王振芳,等.老年冠心病患者PCI相关造影剂肾病的危险因素分析[J].中国临床医学,2022,29(5):813-817.DOI:10.12025/j.issn.1008-6358.2022.20220254.
[15] Chen Z, Mao Q, Xiang L, et al. Iodixanol-associated acute kidney injury and prognosis in patients undergoing elective percutaneous coronary intervention: a prospective, multi-center study[J]. Eur Radiol, 2023, 33(12): 9444-9454. DOI: 10.1007/s00330-023-09964-8.
[16] Rey A, Gras-Champel V, Choukroun G, et al. Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries[J]. Fundam Clin Pharmacol, 2022, 36(4):750-761. DOI: 10.1111/fcp.12758.
[17] Ma X, Mo C, Li Y, et al. Systemic immune-inflammation index associated with contrast-induced nephropathy after elective percutaneous coronary intervention in a case-control study[J]. Coron Artery Dis, 2023, 34(6): 432-440. DOI: 10.1097/MCA.0000000000001253.
[18] 张慧,孙素娟,毕媛晓,等. 远程缺血预适应对经皮冠状动脉介入治疗患者的心肌保护作用[J]. 中国心血管病研究,2022,20(1):30-35. DOI:10.3969/j.issn.1672-5301.2022. 01.006.
[19] 刘有慧,鲜文. NT-proBNP联合hsCRP对老年冠心病患者PCI后造影剂肾病的预测价值[J]. 心血管康复医学杂志,2021,30(5):567-571. DOI:10.3969/j.issn.1008-0074. 2021.05.14.
[20] 李新,樊民. 重组人脑利钠肽对急性心肌梗死合并心力衰竭病人介入术后造影剂肾病的影响[J]. 中西医结合心脑血管病杂志,2023,21(2):217-221. DOI:10.12102/j.issn.1672- 1349.2023.02.005.
[21] 张建秀,曹倩,张振英,等. CM/eGFR、GGT与PCI术后造影剂肾病的关系[J]. 中西医结合心脑血管病杂志,2022,20(6):1083-1087. DOI:10.12102/j.issn.1672-1349.2022.06.031.
[22] 施春丽,薛成年,王晶晶,等. 糖尿病合并急性心肌梗死患者PCI术后造影剂肾病的危险因素及SHI、HbA1c的预测价值研究[J]. 现代生物医学进展,2023,23(7):1374-1379,1390. DOI:10.13241/j.cnki.pmb.2023.07.034.
[23] Gao Z, Zhang Z, Gu D, et al. Hemin mitigates contrast-induced nephropathy by inhibiting ferroptosis via HO-1/Nrf2/GPX4 pathway[J]. Clin Exp Pharmacol Physiol, 2022, 49(8): 858-870. DOI: 10.1111/1440-1681. 13673.
[24] 祁兴敏,安惠旒,王瑞,等. UACR联合血清KIM-1、NGAL对冠心病病人术后并发造影剂肾病的预测分析[J]. 蚌埠医学院学报,2023,48(2):178-181. DOI:10.13898/j.cnki.issn.1000-2200.2023.02.009.
[25] 谢依嶷,赵志权,宁燕虹,等. 慢性肾病患者血液透析治疗后造影剂肾病的发生情况及其与UACR、CM/eGFR水平和MACE发生率的关系[J]. 国际泌尿系统杂志,2022,42(4):702-705. DOI:10.3760/cma.j.cn431460-20210927- 00188.
|